List of references supporting the HMPC assessment on

(1) German monograph of Frangulae cortex (Faulbaumrinde), BanzNr. 133 vom 21.07.1993

(2) Bundesinstitut für Arzneimittel und Medizinprodukte. Bekanntmachung über die Zulassung und Registrierung von Arzneimitteln – Abwehr von Arzneimittelrisiken, Stufe II – Humanarzneimitteln zur innerlichen Anwendung, ausgenommen nach HAB 1 hergestellte homöopathische Arzneimittel, welche Drogen, Drogenzubereitungen oder isolierte Inhaltsstoffe der Anthranoid- (Hydroxyanthracenderivat-)haltigen Pflanzengattungen Andira, Cassia, Rhamnus, Rheum oder Aloe enthalten (German pharmacovigilance actions for anthranoide-containing laxatives) vom 21. Juni 1996, Bundesanzeiger vom 05.07.1996 Nr. 123, Seite 7581

(3) ESCOP monograph "Frangulae Cortex" (Frangula Bark), 2nd edition 2003, Thieme Verlag Stuttgart, New York

(4) Tarpila S et al. Efficacy of ground flaxseed on constipation in patients with irritable bowel syndrome. Current Topics in Nutraceutical Research 2004; 2: 119 - 25

(5) Lemli J. Studies in the field of drugs containing anthracene derivatives. IX. The anthraquinones and dianthrones in Rhamnus frangula. Lloydia 1965; 28: 63 - 7

(6) Van Os FHL. Anthraquinones derivatives in vegetable laxatives. Pharmacology 1976; 14 (Suppl 1): 7 - 17

(7) Longo R. Activity and metabolism of the content from *Rhamnus frangula* bark in the mouse and of synthetic products having an anthraquinone structure. Bolletino Chimico Farmaceutico (Italy) 1980; 119: 669 - 89

(8) De Witte P. Metabolism and pharmacokinetics of anthranoids. Pharmacology 1993; 47 (Suppl. 1): 86 - 97

(9) Ewe K. Obstipation und Laxanzien. Dtsch. Apoth. Ztg. 1994; 134: 825 - 33

(10) Gabler F. Obstipation und Laxanzien. PTA heute 8,1994; 5: 380 - 8

(11) Cresseri A et al. Biologische Wertbestimmung der laxativen Wirkung der Polyhydroxy-Anthrachinone aus der Rinde von Rhamnus frangula L. Archiv der Pharmazie 299. Bd. 1966/7: 615 - 8

(12) HagerROM 2003, Springer Verlag, Heidelberg: Frangulae cortex (Faulbaumrinde)

(13) Vogel G. Arzneim Forsch 1974; 25: 1356 - 65, cited in HagerROM 2003, Springer Verlag, Heidelberg: Frangulae cortex (Faulbaumrinde)

(14) Schultz OE. Pharmazie 1950; 5: 501 - 7, cited in HagerROM 2003, Springer Verlag, Heidelberg: Frangulae cortex (Faulbaumrinde)

7 Westferry Circus, Canary Wharf, London, E14 4HB, UK
Tel. (44-20) 74 18 84 00 Fax (44-20) 75 23 70 51
E-mail: mail@emea.europa.eu http://www.emea.europa.eu

(15) Guérin JC, Réveillière HP. Antifungal activity of plant extracts used therapeutically. I. Study of 41 extracts against 9 fungi species. Ann Pharm Fr 1984; 42: 553 - 9

(16) Sydiskis RJ et al. Inactivation of enveloped viruses by anthraquinones extracted from plants. Antimicrobial agents and chemotherapy 1991; 35 (12): 2463 - 6

(17) Teng CM et al. Frangulin B, an antagonist of collagen-induced platelet aggragation and adhesion, isolated from Rhamnus formosana. Thrombosis and haemostasis 1993; 70 (6): 1014 - 8

(18) Wei BL et al. In vitro anti-inflammatory effects of quercetin 3-O-methyl ether and other constituents from Rhamnus species. Planta med 2001; 67 (8): 745 - 7

(19) Fotiades P et al. Die Behandlung der chronischen Obstipation mit Laxariston Granulat bei Patienten des rheumatischen Formenkreises. Treatment of chronic constipation with Laxariston granules in patients with rheumatic diseases. Medizinische Welt 1976; 27 (30): 1441 - 5

(20) Bauer H. Behandlung der Obstipation mit Laxariston in der gynäkologischen Praxis. Treatment of obstipation in gynecological practice with Laxariston. Therapie der Gegenwart 1977; 116 (12): 2305 - 12

(21) Gracza L et al. Behandlungsergebnisse mit den Phytopharmaka Bilicura und Spasmo-Bilicura bei Störungen des Leber-Galle-Verdauungssystems. Therapeutic results with Bilicura and Spasmo-Bilicura in diseases of the hepatocholegastroenteral system. Fortschritte der Medizin 1977; 95 (47-48): 2829 - 31

(22) Arndt EM. Über die Behandlung klimakterischer Beschwerden mit einem hormonfreien Arzneimittel. Treatment of climacteric complaints with a hormone-free medicine. Ärztezeitschrift für Naturheilverfahren 1982; 23 (1): 45 - 9

(23) Manojlovic NT et al. Antifugal activity of Rubia tinctorum, Rhamnus frangula and Caloplaca cerina. Fitoterapia 2005; 76 (2): 244 - 6

(24) Williams CL et al. A summary of conference recommendations on dietary fiber in childhood: Conference on Dietary Fiber in Childhood, New York (New York, USA), May 24, 1994. Pediatrics 1995; 96: 1023 - 28

(25) Feldman H et al. Trial of deglycyrrhizinated licorice (glycyrrhiza) in the treatment of duodenal ulcer. Gut 1971; 12: 449 - 51

(26) Bruggeman IM et al. Lack of activity of the bacterial mutagen emodin in HGPRT and SCE assay with V79 Chines hamster cells. Mutation research 1984; 138 (2-3): 219 - 24

(27) Westendorf J et al. Genotoxicity of naturally occurring hydroxyanthraquinones. Mutation Research 1990; 240: 1 - 12

(28) Helmholz H et al. Genotoxizität der Faulbaumrinde. Genotoxicity of buckthorn bark. Pharmazeutische Zeitung 1993; 138 (Oct 28): 48 - 50

(29) Heidemann A et al. The Genotoxicity Status of Senna. Pharmacology 1993; 47 (Suppl. 1): 178 - 86

(30) Faber P et al. Relevance of rhein excretion into breast milk. Pharmacology 1988; 36 (Suppl. 1) 212 - 20

(31) Gerhard Madaus. Lehrbuch der biologischen Heilmittel Band I, 1938; Frangula: p. 1369 - 77. Reprint Georg Olms Verlag Hildesheim New York 1976

(32) The British Pharmaceutical Codex, published by direction of the Council of the Pharmaceutical Society of Great Britain, 1911. FRAGULAE CORTEX

(33) The Dispensatory of the United States of America, edited by Joseph P. Remington, Horatio C. Wood and others, 1918: Frangula. U.S.

(34) The Eclectic Materia Medica, Pharmacology and Therapeutics. Harvey Wickes Felter, M.D. 1922. Frangula

(35) David M.R. Culbreth, Ph.G., M.D. A Manual of Materia Medica and Pharmacology. 7th edition, 1927. Rhamus frangula

(36) Hagers Handbuch der Pharmazeutischen Praxis. Dr. G. Frerichs, G. Arends, Dr. H. Zörnig (Herausgeber). Verlag von Julius Springer, Berlin 1927. Frangula

(37) Handbuch der praktischen und wissenschaftlichen Pharmazie. Hermann Thoms (Herausgeber). Urban & Schwarzenberg, Berlin, Wien 1927. *Rhamnus frangula* L.

(38) Fischer, Georg. Heilkräuter und Arzneipflanzen. 3. Auflage 1966. Karl F. Haug Verlag, Ulm/Donau.

(39) Dragendorf, Georg. Die Heilpflanzen der verschiedenen Völker und Zeiten. Werner Fritsch, München 1967.

(40) Martindale – The Extra Pharmacopoiea – 25th ed 1967. By Norman W. Blacow. London. The pharmaceutical press

(41) Siegers CP et al. Anthranoid laxative abuse – A risk for colorectal cancer? Gut 1993; 34 (8): 1099 - 101

(42) Kune GA et al. The role of chronic constipation, diarrhea, and laxative use in the etiology of large-bowel cancer. Data from the Melbourne Colorectal Cancer Study. Diseases of the colon and rectum 1988; 31 (7): 507 - 12

(43) Kune GA. Laxative use not a risk for colorectal cancer: data from the Melbourne Colorectal Cancer Study. Zeitschrift für Gastroenterologie 1993; 31 (2): 140 - 3

(44) Nusko G et al. Retrospective study on laxative use and melanosis coli as risk factors for colorectal neoplasma. Pharmacology 1993; 47 Suppl 1: 234 - 41

(45) Sonnenberg A, Müller AD. Constipation and cathartics as risk factors of colorectal cancer: a meta-analysis. Pharmacology 1993; 47 (Suppl. 1): 224 - 33

(46) Loew D et al. Anthranoid laxatives: cause of colorectal cancer? Deutsche Apotheker-Zeitung 1994; 134 : 30, 32 - 3

(47) Nusko G et al. Anthranoide laxative use is not a risk factor for colorectal neoplasia: results of a prospective case control study. Gut 2000; 46: 651 - 5

(48) Willems M et al. Anthranoid self-medication causing rapid development of melanosis coli. The netherlands journal of medicine 2003; 61 (1): 22 - 4

(49) Nilsson SE et al. Laxative treatment elevates plasma homocysteine: A study on a population-based Swedish sample of old people. European Journal of Clinical Pharmacology 2004; 60 (1): 45 - 9

(50) Jae Sik Joo et al. Alterations in colonic anatomy induced by chronic stimulant laxatives: The cathartic colon revisited. Journal of Clinical Gastroenterology 1998; 26 (4): 283 - 6

(51) Van Gorkom BA et al. Review article: anthranoid laxatives and their potential carcinogenic effects. Alimentary pharmacology & therapeutics 1999; 13 (4): 443 - 52

(52) Sitzmann FC et al. Lokale Nebenwirkungen an der Haut durch Anthraglykoside. Pädiatr Prax 1979; 21: 355 - 8

(53) Dahlmann W et al. Lähmungen, organisches Psychosyndrom und Herzrhythmusstörungen bei extremer Kaliumverarmung durch chronischen Laxantienabusus. Paralysis, organic brain syndrom, and cardiac dysrhythmias caused by chronic laxative abuse. Deutsche Medizinische Wochenzeitschrift 1977; 102 (43): 1555 - 9

(54) Goodman & Gilman's. The Pharmacological Basis of Therapeutics. Eleventh edition. Section VI / Drugs affecting gastrointestinal function. Stimulant (Irritant) Laxatives

(55) Capasso F et al. Effect of indomethacin on aloin and 1,8 dioxianthraquinone-induced production of prostaglandins in rat isolated colon. Prostaglandins 1983; 26 (4): 557 - 62

(56) Jahnke GD et al. Developmental toxicity evaluation of emodin in rats in mice. Birth Defects Research Part B – Developtmental and Reproductive Toxicology 2004; 71 (2): 89 - 101

(57) NTP Technical Report on the Toxicology and Carcinogenesis Studies of Emodin in F344/N Rats and $B6C3F_1$ Mice. National Toxicology Program, June 2001, NTP TR 493, NIH Publication No. 01-3952

(58) Bachmann M et al. Toxicity and mutagenicity of molds of *Aspergillus glaucus* group. Identification of physcion and three related anthraquinones as main constituents from *Aspergillus chevalieri*. J. Agric. Food Chem. 1979; 27: 1342 - 7

(59) Mengs U et al. Lack of emodin genotoxicity in the mouse micronucleus assay. Mutation Research 1997; 393: 289 - 93

(60) Masuda T et al. 2-Hydroxyemodin, an active metabolite of emodin in the hepatic microsomes of rats. Mutation Research 1985; 149: 327 - 32

(61) Wang HH, Chung JG. Emodin-induced inhibition of growth and DNA damage in the Heliobacter pylore. Current microbiology 1997; 35 (5): 262 - 6

(62) Zhang L et al. Emodin inhibits growth of human breast cancer cells and induces morphological differentiation of these cells by its suppression of HER-2/neu tyrosine kinase activity. Proc Am Assoc Cancer Res 1995; 36 (86 Meet): 435

(63) Zhang L et al. Suppressed transformation and induced differentiation of HER-2/neu-overexpressing breast cancer cells by emodin. Cancer research 1995; 55 (17): 3890 - 6

(64) Zhang L, Hung MC. Sensitization of HER-2/neu-overexpressing non-small cell lung cancer cells to chemotherapeutic drugs by tyrosine kinase inhibitor emodin. Oncogene 1996; 12 (3): 571 - 6

(65) Zhang L et al. Tyrosine kinase inhibitor emodin suppresses growth of HER-2/neu overexpressing breast cancer cells in athymic mice and sensitizes these cells to the inhibitory effect of paclitaxel. Clinical Cancer Research 1999; 5: 343 - 53

(66) Fenig E et al. Combined effect of aloe-emodin and chemotherapeutic agents on the proliferation of an adherent variant cell line of Merkel cell carcinoma. Oncology reports 2004; 11 (1): 213 - 7

(67) Vyth A and Kamp PE. Detection of anthraquinone laxatives in the urine. Pharm Weekbl SCI ED 1979; No.2: 456 - 9

(68) Haverkamp W et al. Medikamentenbedingte QT-Verlängerung und Torsade de pointes. Drug-induced QT Prolongation and Torsade de Pointes. Deutsche Ärzteblatt 2002; 99: A 1972-9 [Heft 28 - 9]

(69) Konsensuspapier Expertenforum: Obstipation und Laxanzien. Praxis 1999; 88: 1269 - 74

(70) Jacobs EJ et White E. Constipation, laxative use, and colon cancer among middle-aged adults. Epidemiology 1998; 9: 385 - 91

(71) Roberts MC et al. Constipation, laxative use, and colon cancer in a North Carolina population. Am J Gastroenterol 2003; 98: 857 - 64

(72) Müller-Lissner S. Myths and misconceptions about chronic constipation. Am J Gastroenterol 2005; 100: 232 - 42

(73) Smith B. Effect of irritant purgatives on the myentric plexus in man and mouse. Gut 1968; 9: 139 - 45

(74) Riemann JF et al. The fine structure of colonic submucosal nerves in patients with chronic laxative abuse. Scand J Gastroenterol 1980; 15: 761 - 8

(75) Riemann JF et al. Ultrastructural changes in the gut autonomic nervous system following laxative abuse and in other conditions. Scand J Gastroenterol 1982; 71: 11 - 24

(76) Berkelhammer C et al. Low-volume oral colonoscopy bowel preparation: sodium phosphate and magnesium citrate. Gastrointest Endosc 2002; 56: 89 - 94

(77) Meisel JL et al. Human rectal mucosa: proctoscopic and morphological changes caused by laxatives. Gastroenterology 1977; 72: 1274 - 9

(78) Pockros PJ et al. Golytely lavage versus a standard colonoscopy preparation. Effect on normal colonic mucosal histology. Gastroenterology 1985; 88: 545 - 8

(79) Riecken EO et al. The effect of an anthraquinone laxative on colonic nerve tissue: A controlled trial in constipated women. Z Gastroenterol 1990; 28: 660 - 4

(80) Beuers U et al. Hepatitis after chronic abuse of senna. Lancet (England) 1991; Vo.: 337: 372 - 3

(81) Vanderperren B et al. Acute liver failure with renal impairment related to the abuse of senna anthraquinone glycosides. Ann Pharmacotherapy 2005; 39: 1353 - 7